Cargando…
Emapalumab in primary haemophagocytic lymphohistiocytosis and the pathogenic role of interferon gamma: A pharmacometric model‐based approach
AIM: Primary haemophagocytic lymphohistiocytosis (HLH) is a rare, life‐threatening, hyperinflammatory syndrome generally occurring in early childhood. The monoclonal antibody emapalumab binds and neutralises interferon γ (IFNγ). This study aimed to determine an emapalumab dosing regimen when traditi...
Autores principales: | Jacqmin, Philippe, Laveille, Christian, Snoeck, Eric, Jordan, Michael B., Locatelli, Franco, Ballabio, Maria, de Min, Cristina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305196/ https://www.ncbi.nlm.nih.gov/pubmed/34935183 http://dx.doi.org/10.1111/bcp.15133 |
Ejemplares similares
-
Efficacy and safety of emapalumab in macrophage activation syndrome
por: De Benedetti, Fabrizio, et al.
Publicado: (2023) -
Novel Therapeutic Approaches to Familial HLH (Emapalumab in FHL)
por: Merli, Pietro, et al.
Publicado: (2020) -
Lamotrigine: Haemophagocytic lymphohistiocytosis: case report
Publicado: (2022) -
Alemtuzumab: Haemophagocytic lymphohistiocytosis: case report
Publicado: (2021) -
Haematopoietic Stem Cell Transplantation for Primary Haemophagocytic Lymphohistiocytosis
por: Lehmberg, Kai, et al.
Publicado: (2019)